Methods to improve vector expression and genetic stability

Patent metadata

Field	Value
Publication number	US-9944935-B2
Application number	US-201615133260-A
Country	US
Kind code	B2
Filing date	Apr 20, 2016
Priority date	Mar 29, 2012
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.

First claim

What is claimed is:

1. A method for improving protein expression, vector propagation, and genetic stability in individual vector platforms comprising
(a) developing a gene insert compatible with a canine distemper virus (CDV) host vector comprising:
(i) modifying a protein sequence of the gene insert,
wherein the protein is human immunodeficiency virus (HIV) envelope glycoprotein (Env) or HIVCON,
wherein the protein encoded by the gene insert is expressed from the vector to produce a protein that maintains native structural features; and
wherein the Env or HIVCON gene insert is a hybrid that includes sequences encoding functional domains substituted with sequences encoding analogous functional domains from a CDV fusion protein (F); and
(ii) removing potential T7 polymerase terminators, and
(iii) making one or more modifications to the nucleotide sequence of the gene insert;

(b) cloning the gene insert into the CDV host vector; thereby improving protein expression, vector propagation, and genetic stability in individual vector platforms; and
(c) expressing the protein encoded by the vector in a cell.

2. The method of claim 1 , wherein cis-acting RNA sequences for enhancing translation are added and wherein translation is enhanced in comparison to a vector without the sequences.

3. The method of claim 1 , wherein the one or more modifications to the nucleotide sequence of the gene insert comprises
interrupting one or more homopolymer sequences >5 nucleotides CCCCC and GGGGG by substitution of at least one synonymous codon
modifying the 5′ end of the coding sequences to include a Kozak translation initiation sequence having the sequence of SEQ ID NO: 1;
adding a TAAag translation termination signal to the 3′ end of the coding sequences;
interrupting RNA instability elements comprising UUAUUUAUU by replacement with synonymous codons;
interrupting a potential polyadenylation signal comprising AAUAAA by substitution with synonymous codons; and/or
removing potential T7 RNA polymerase terminators cTGAg, gacTAAag, ctTAAac and gacTAAat to prevent inhibition of recombinant-CDV rescue from cloned DNA.

4. The method of claim 1 further comprising:
(d) measuring binding of the protein to antibodies specific to the native structural features of the gene insert.

5. The method of claim 1 , wherein the HIV Env is Subtype A Env or Subtype C Env.

6. The method of claim 5 , wherein the HIV Env is from strain BG505.

7. The method of claim 5 , wherein the one or more modifications to the nucleotide sequence of a HIV Env gene further comprises
generating a synthetic Env gene with a codon optimized nucleotide content using CDV codon bias retrieved from a database;
predicting potential mRNA splice sites and substituting synonymous codons; and/or
adjusting insert length to ensure that introducing the total CDV genome length is multiples of six.

8. The method of claim 5 , wherein the Subtype C Env is further modified to generating coding sequences for a hybrid Env protein containing one or more domains obtained from CDV F thereby generating an Env-F protein.

9. The method of claim 1 , wherein the protein is HIVCON.

10. The method of claim 9 , wherein the one or more modifications to the nucleotide sequence of a HIVCON gene further comprises
modifying the HIVCON gene with a CDV codon bias with viral transcription start and stop signals flanking the HIVCON gene;
modifying the HIVCON gene for insertion downstream of the CDV P gene;
fusing the HIVCON coding sequence to the Matrix (M) gene of CDV to form a polycistronic coding sequence, optionally inserting a 2A-like element between the HIVCON and M coding sequence;
interrupting morbillivirus transcription stop or start signals using an alternative codon;
and/or
adding a (vesicular stomatitis virus (VSV) signal peptide to the N-terminus of the HIVCON gene.

11. The method of claim 9 , wherein the nucleotide sequence encoding HIVCON comprises SEQ ID NO: 7.

Assignees

• Int Aids Vaccine Initiative

Inventors

• Parks Christopher L
• Wright Kevin J
• Yuan Maoli
• Jurgens Christy K
• Zhang Xinsheng
• Domi Arban
• Hoffenberg Simon
• Chiuchiolo Maria J
• Rabinovich Svetlana
• Wilson Aaron J
• Lorenz Ivo C

Classifications

• A61K39/21

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• C12N15/68 Primary

  Stabilisation of the vector · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/12

  Viral antigens · CPC title